These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24432379)

  • 1. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
    Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
    Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
    Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
    Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
    Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
    Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
    Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
    Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
    Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of synergistic drug combinations using breast cancer patient-derived xenografts.
    Turner TH; Alzubi MA; Harrell JC
    Sci Rep; 2020 Jan; 10(1):1493. PubMed ID: 32001757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
    Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
    Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
    Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
    Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
    Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
    Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
    Gao JZ; Chen FH; Wang L; Wei H; Meng SL
    Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.
    Kudchadkar R; Ernst S; Chmielowski B; Redman BG; Steinberg J; Keating A; Jie F; Chen C; Gonzalez R; Weber J
    Cancer Med; 2015 May; 4(5):643-50. PubMed ID: 25533314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
    Zhao X; Puszyk WM; Lu Z; Ostrov DA; George TJ; Robertson KD; Liu C
    Mol Cancer Ther; 2015 Jan; 14(1):80-9. PubMed ID: 25344582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
    Ueno T; Uehara S; Nakahata K; Okuyama H
    Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Kinoyama I; Matsuhisa A; Kudou M; Sasamata M
    Cancer Sci; 2011 Mar; 102(3):614-21. PubMed ID: 21205082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
    Huang J; Lyu H; Wang J; Liu B
    Cancer Lett; 2015 Oct; 366(2):160-72. PubMed ID: 26123662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.